The presentation reinforces the company's strategy to partner its clinical assets. No near-term catalyst identified; monitor for partnership announcements for IMM-529, which could provide upfront payments and milestone-based value.
Price Chart
Executive Summary
Immuron Ltd filed a 6-K with an investor presentation highlighting FY26 global sales revenue of A$7.7 million (up 6% YoY), cash of A$10.0 million, and a strategic decision to partner its two clinical-stage assets (IMM-124E and IMM-529). The presentation is routine and contains no new material financial guidance.
Key Facts
- FY26 global sales revenue of A$7.7 million, up 6% on prior year
- Australia sales A$5.8 million, up 10% YoY
- US sales A$1.8 million, up 7% (13% in USD)
- Canada sales A$0.2 million, down 55% YoY
- Cash of A$10.0 million as of 31 December 2025
- EBITDX (ex-R&D) for HY26 was -A$1.1 million
- Strategic decision to partner IMM-124E and IMM-529 for development and commercialization
- IMM-124E eligible for end of Phase 2 meeting with FDA; Lumanity peak US sales estimate of US$102 million
- IMM-529 IND approved for Phase 2; Lumanity peak US sales estimate of US$400 million
- Pullan Consulting engaged to support partnering IMM-529
Financial Impact
FY26 global sales of A$7.7M (up 6% YoY); cash A$10.0M; no new guidance provided
Risk Factors
- Clinical trial risks for IMM-529 and IMM-124E
- Dependence on successful partnership agreements
- Cash burn rate given negative EBITDX and reliance on R&D tax incentives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-081582 |
| Document: ea0299306-6k_immuron.htm | 0001213900-26-081582 |
| Document: 0001213900-26-081582-index-headers.html | 0001213900-26-081582 |
| Document: 0001213900-26-081582-index.html | 0001213900-26-081582 |
| Document: 0001213900-26-081582.txt | 0001213900-26-081582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9738 (+4.71%) |
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9738 (+4.48%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9738 (+4.48%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9738 (+2.61%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9738 (−0.85%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9738 (−6.37%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9738 (−18.17%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9738 (−18.17%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9738 (−22.41%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9738 (−45.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers